Lenzilumab 治疗住院 COVID-19 肺炎的 3 期随机对照试验
LIVE-AIR 是一项 3 期随机双盲安慰剂对照试验,纳入 520 例不需要有创机械通气的住院 COVID-19 肺炎成人患者,比较 lenzilumab(抗 GM-CSF 单抗)与安慰剂的疗效与安全性。mITT 人群 479 例中,lenzilumab 组第 28 天无有创通气存活率高于安慰剂组,安全性与安慰剂相似。
要点
- lenzilumab 组第 28 天无有创通气存活率为 84%,安慰剂组为 78%。
- 在标准治疗(含激素和瑞德西韦)基础上加用 lenzilumab 的额外价值仍不明确。
核心结论
- lenzilumab 显著改善住院 COVID-19 肺炎患者第 28 天无有创机械通气的存活,安全性特征与安慰剂相似。
- lenzilumab 在激素等免疫调节剂之外的附加价值仍未知。
研究设计与样本
- 3 期随机双盲安慰剂对照试验,在美国和巴西 29 个中心开展。
- 纳入不需要有创机械通气的住院 COVID-19 肺炎成人患者,1:1 随机分组。
- lenzilumab 组给予 3 次静脉给药,每次 600 mg,间隔 8 小时;所有患者接受标准支持治疗。
- 筛选 528 例,520 例随机纳入意向治疗人群,479 例纳入改良意向治疗(mITT)主要分析。
- 主要终点为 mITT 人群第 28 天无有创机械通气存活,按年龄和疾病严重程度随机分层。
主要发现
- mITT 中 lenzilumab 组 198 例(84%;95%CI 79-89)达到第 28 天无有创通气存活,安慰剂组 190 例(78%;95%CI 72-83)。
- lenzilumab 组 255 例中 68 例(27%)、安慰剂组 257 例中 84 例(33%)发生至少 1 次 CTCAE ≥3 级不良事件。
- 最常见的 ≥3 级治疗中出现不良事件为呼吸系统疾病(26%)和心脏疾病(6%),均未导致死亡。
- 基线时男性 311 例(65%),平均年龄 61 岁(SD 14),CRP 中位数 79 mg/L(IQR 41-137);449 例(94%)使用激素,347 例(72%)使用瑞德西韦,331 例(69%)两者均用。
临床怎么用
- 对于不需要有创机械通气的住院 COVID-19 肺炎患者,可考虑在标准治疗基础上加用 lenzilumab 以改善无有创通气存活。
- 用药时需关注呼吸系统和心脏相关的不良事件。
局限性
- lenzilumab 在激素等其他免疫调节剂之外的附加价值仍不明确。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the inflammatory processes. Lenzilumab, a GM-CSF neutralising monoclonal antibody, was investigated in the LIVE-AIR trial to assess its efficacy and safety in treating COVID-19 beyond available treatments. METHODS: In LIVE-AIR, a phase 3, randomised, double-blind, placebo-controlled trial, hospitalised adult patients with COVID-19 pneumonia not requiring invasive mechanical ventilation were recruited from 29 sites in the USA and Brazil and were randomly assigned (1:1) to receive three intravenous doses of lenzilumab (600 mg per dose) or placebo delivered 8 h apart. All patients received standard supportive care, including the use of remdesivir and corticosteroids. Patients were stratified at randomisation by age and disease severity. The primary endpoint was survival without invasive mechanical ventilation to day 28 in the modified intention-to-treat population (mITT), comprising all randomised participants who received at least one dose of study drug under the documented supervision of the principal investigator or sub-investigator. Adverse events were assessed in all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, NCT04351152, and is completed. FINDINGS: Patients were enrolled from May 5, 2020, until Jan 27, 2021. 528 patients were screened, of whom 520 were randomly assigned and included in the intention-to-treat population. 479 of these patients (n=236, lenzilumab; n=243, placebo) were included in the mITT analysis for the primary outcome. Baseline demographics were similar between groups. 311 (65%) participants were males, mean age was 61 (SD 14) years at baseline, and median C-reactive protein concentration was 79 (IQR 41-137) mg/L. Steroids were administered to 449 (94%) patients and remdesivir to 347 (72%) patients; 331 (69%) patients received both treatments. Survival without invasive mechanical ventilation to day 28 was achieved in 198 (84%; 95% CI 79-89) participants in the lenzilumab group and in 190 (78%; 72-83) patients in the placebo group, and the likelihood of survival was greater with lenzilumab than placebo (hazard ratio 1·54; 95% CI 1·02-2·32; p=0·040). 68 (27%) of 255 patients in the lenzilumab group and 84 (33%) of 257 patients in the placebo group experienced at least one adverse event that was at least grade 3 in severity based on CTCAE criteria. The most common treatment-emergent adverse events of grade 3 or higher were related to respiratory disorders (26%) and cardiac disorders (6%) and none led to death. INTERPRETATION: Lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with COVID-19, with a safety profile similar to that of placebo. The added value of lenzilumab beyond other immunomodulators used to treat COVID-19 alongside steroids remains unknown. FUNDING: Humanigen.
引用
- Temesgen Z, Burger CD, Baker J, et al. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respir Med. 2021. PMID: 34863332. doi:10.1016/S2213-2600(21)00494-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。